Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPEN-03: ALX148 plus pembrolizumab in first-line PD-L1-positive recurrent/metastatic HNSCC
NL-OMON56262Phase 2Recruiting
- Sponsor
- ALX Oncology
- Start
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of evorpacept and pembrolizumab in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by ALX Oncology. Primary endpoints: 12-month overall survival rate and Objective response rate. Started Dec 2022; status: recruiting.
02
Drugs
evorpaceptpembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON56262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56262.